✦ LIBER ✦

Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia

✍ Scribed by Yavuz Beyazit; Salih Aksu; Murat Kekilli; Ibrahim C. Haznedaroglu; Sadettin Kilickap; Hakan Goker

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 107 KB
Volume: 79
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.20274

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocytic sarcoma giant in chronic my

Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy

✍ Rita de Cássia RosáRio Cavalheiro; Perla Vicari; Fernanda Maria Morselli; Lariss 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 2 views

Successful treatment of chronic myeloid

Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis

✍ Evren Ozdemir; Yener Koc; Emin Kansu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB 👁 2 views

Imatinib mesylate induces hypophosphatem

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

✍ S. Osorio; A. García Noblejas; A. Durán; J.L. Steegmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Inv (11)(p15q21) in donor-derived Ph-neg

Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation

✍ Bruno C. Medeiros; Kathy Chun; Suzanne Kamel-Reid; Jeffrey Lipton 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract Imatinib mesylate (IM) is the standard first‐line treatment for patients with chronic myeloid leukemia (CML). Surprisingly, 2–15% of patients achieving a complete cytogenetic response develop cytogenetic abnormalities in Philadelphia (Ph)‐negative cells. Following hematopoietic stem cel

Imatinib as the first-line treatment of

Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

✍ Daniela Zackova; Hana Klamova; Ladislav Dusek; Jan Muzik; Katerina Machova Polak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views